TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06630988

Intervention type: OTHER
Intervention: Failure rates
Description: Describe the management failure rate for hand infections, including panariasis, phlegmons and arthritis.
Study: NCT06630845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose F18
Description: Given IV as part of routine imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)
Description: Imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)
Description: Imaging procedure done concurrently with PET/MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Electric (GE) SIGNA PET/MR
Description: Imaging device
Study: NCT06630715

Intervention type: DRUG
Intervention: Upadacitinib 15 MG [Rinvoq]
Description: 15 mg/ day

Intervention type: DRUG
Intervention: Upadacitinib 15 MG [Rinvoq]
Description: 15 mg/ day
Study: NCT05252247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immobilisation
Description: Eight hours prior to attending the immobilisation session, a splint will be fitted to the hand of the participant and remain until the session start.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight hours prior to attending the exercise session, the participant will be instructed to perform 150 ballistic finger movements every hour until the session start.
Study: NCT04552912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Build Stamina Program
Description: Build StaMINA intervention is a self-management intervention that provides information, motivation, behavioral skills to engage in PA, and ultimately a tailored PA program for adults with AL who are receiving consolidation/maintenance chemotherapy.
Study: NCT05178914

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Treatment adaptation
Description: Patients will benefit from intensified treatment or de escalation treatment according to the result of the index of microcirculatory resistance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment adaptation
Description: Patients will benefit from intensified treatment or de escalation treatment according to the result of the index of microcirculatory resistance
Study: NCT04526899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT111
Description: IV injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT111
Description: IV injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IV infusion
Study: NCT05802446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time fMRI Neurofeedback
Description: Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant. With this feedback on brain activity, subjects can learn to control the activity of selected brain areas. Trial after trial, participants develop their individual strategies to voluntarily regulate the signal. The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback. By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Real-time fMRI Neurofeedback
Description: Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant. With this feedback on brain activity, subjects can learn to control the activity of selected brain areas. Trial after trial, participants develop their individual strategies to voluntarily regulate the signal. The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback. By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
Study: NCT05005533

Intervention type: OTHER
Intervention: Observational
Description: Chronic Obstructive Pulmonary Disease Severity of Individuals by Chronic Obstructive Pulmonary Disease Assessment Test, shortness of breath Modified Medical Research Council scale, cough related quality of life Leicester Cough Questionnaire, respiratory muscle strength with Maximum Inspiratory and Expiratory Pressure, Posture with Spinal Mouse device, pain with Visual Analog Scale, severity of fatigue Fatigue Physical performance of the lower extremities will be evaluated with the Short Physical Performance Test, functional mobility will be evaluated with the Time Up and Go Test, and balance will be evaluated with the Biodex Balance System

Intervention type: OTHER
Intervention: Observational
Description: Chronic Obstructive Pulmonary Disease Severity of Individuals by Chronic Obstructive Pulmonary Disease Assessment Test, shortness of breath Modified Medical Research Council scale, cough related quality of life Leicester Cough Questionnaire, respiratory muscle strength with Maximum Inspiratory and Expiratory Pressure, Posture with Spinal Mouse device, pain with Visual Analog Scale, severity of fatigue Fatigue Physical performance of the lower extremities will be evaluated with the Short Physical Performance Test, functional mobility will be evaluated with the Time Up and Go Test, and balance will be evaluated with the Biodex Balance System
Study: NCT06278324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Spray HSV Treatment
Description: Nasal treatment with the nasal spray Humer Stop Virus for 7 days, 2-3 puffs per nostril, 3-4 per day, space applications 4 hours apart.
Study: NCT06630754

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No intervention; observation cohort study
Study: NCT06629935

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthognathic surgery
Description: Le Fort I surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthognathic surgery
Description: Le Fort I surgery
Study: NCT06402487

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Propionic acid 1000 mg capsule
Description: Patients will be assigned to propionic acid or placebo as add on MS treatment.
Study: NCT06632158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindBoba
Description: MindBoba is a smartphone app that uses strategies based on Problem-Solving Therapy to help decrease stress and anxiety, and teach new skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindshift CBT
Description: MindShift® CBT uses strategies based on Cognitive Behavioural Therapy (CBT) to help you learn to relax and be mindful, develop more effective ways of thinking, and use active steps to take charge of your anxiety.
Study: NCT06631313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureWick System
Description: The PureWick System consists of the PureWick Urine Collection System used with either the PureWick Male External Catheter or the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
Study: NCT06402487

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be assigned to propionic acid or placebo as add on MS treatment.
Study: NCT04827030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaïne Hydrochloride by Erector Spinae block
Description: Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaïne Hydrochloride by Paravertebral block
Description: Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
Study: NCT06631742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming on Dividat Senso
Description: The active dance video game is played with the Dividat Senso (Dividat \| Senso: cognitive-motor training). It consists of a dance disc with four arrows (up, down, left, right), and the game is played on a large screen (which is connected to the PC). The screen indicates which arrow the person should step on, thus controlling the game through body movements. The games give the person feedback in the form of auditory, visual, and somatosensory stimuli.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Standardised care with meal service, individual activities (e.g. hiking group, walking group, exercise group, handicrafts, gardening group, singing, painting or lunch) and customized care and support as required.
Study: NCT06569524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA2225/AP025 or TQA2225/AP025 Placebo 25mg
Description: To evaluate the efficacy and safety of TQA2225/AP025 (25mg) in patients with Non-Alcoholic Steatohepatitis (NASH)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA2225/AP025 or TQA2225/AP025 Placebo 50mg
Description: To evaluate the efficacy and safety of TQA2225/AP025 (50mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
Study: NCT06094296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986315
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986315
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986315
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986315
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT06505031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: Oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-861-matching placebo tablet.
Study: NCT06250816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The hospital gown with cartoon characters
Description: The patient will be asked to choose one of the hospital gowns with cartoon characters they want to wear and put it on with parental assistance.
Study: NCT06094296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study: NCT04647864

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation
Description: Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
Study: NCT04862429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast enhanced mammography guided biopsy (diagnostic procedure)
Description: With visible contrast-enhancement, stereotactic biopsy will be performed under CESM guidance. After administration of an additional dose of iodized contrast-enhancement (Omnipaque), the insertion of the biopsy needle and the biopsy sampling will be targeted on the area of greatest enhancement in the context of calcifications. In the absence of contrast-enhancement, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area. At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mammography guided biopsy (diagnostic procedure)
Description: For all lesions, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area.~At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).
Study: NCT06746090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Group A(Intervention): Patients who will be reminded daily via whatsapp text message.~Group B(Intervention): Patients who will be asked through a weekly phone call about elastic wear and then motivated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Group A(Intervention): Patients who will be reminded daily via whatsapp text message.~Group B(Intervention): Patients who will be asked through a weekly phone call about elastic wear and then motivated.
Study: NCT06629792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Cleanser
Description: The cleanser was instructed to be used twice daily over the course of 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer
Description: The Moisturizer was instructed to be applied to the global face twice daily over the course of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sunscreen SPF 30
Description: The Sunscreen was instructed to be applied once daily in the morning, with re-application with extended sun exposure per FDA guidelines over the course of 12 weeks.
Study: NCT06094296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified days
Study: NCT06177184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Human Milk - Nutritional Replacement
Description: All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking Association of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
Study: NCT06631157

Intervention type: DEVICE
Intervention: Essential pro
Description: Patients in whom treatment with (Essential Pro) has been attempted
Study: NCT05357365

Intervention type: OTHER
Intervention: questionnaire survey
Description: Questionnaire survey about occupational, mental, physical factors on one's health.

Intervention type: OTHER
Intervention: questionnaire survey
Description: Questionnaire survey about occupational, mental, physical factors on one's health.
Study: NCT06404671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed interval cytoreductive surgery (DICS)
Description: patients will receive six courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by delayed interval cytoreductive surgery (DICS) within 6 weeks of the last cycle of chemotherapy. After DICS, patients will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early interval cytoreductive surgery (EICS)
Description: patients will receive three courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by early interval cytoreductive surgery (EICS) within 6 weeks of the last cycle of chemotherapy. After EICS, patients will receive adjuvant three courses of intravenous carboplatin and paclitaxel every 3 weeks, then will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks.
Study: NCT05531383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.
Study: NCT06557187

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
Description: hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
Study: NCT05408455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMST150 (Expiratory muscle training)
Description: Respiratory exercise device (Expiratory muscle trainer) developed for the expiratory muscles, and resistant expiratory muscle training were applied. Threshold loading was applied to the cases at approximately 30% of the respiratory muscle strength values measured in the 1st week. In respiratory muscle training, the pressure value was increased according to the tolerance of the patient and training was given at a pressure value between 50-75%. The subjects were asked to do 10 vigorous expirations at the adjusted pressure value by doing normal inspiration for expiratory muscle training in a comfortable sitting position. This program was applied in 3 sets in the same way for approximately 30 minutes. It was continued 3 days a week for 8 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham EMST150 (Expiratory muscle training)
Description: The subjects were asked to perform normal inspiration and then exhale 10 times for expiratory muscle training without threshold loading. This program was applied in 3 sets in the same way for approximately 30 minutes. It will continue 3 days a week for 8 weeks
Study: NCT06631456

Intervention type: OTHER
Intervention: PRP injection
Description: A total of 3 doses of intra-articular PRP were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.

Intervention type: OTHER
Intervention: Ozone therapy
Description: A total of 3 doses of intra-articular ozone therapy were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
Study: NCT04791124

Intervention type: OTHER
Intervention: Electroencephalography
Description: EEG evaluation Composed by three consecutive tests~1. Resting state EEG, with either eyes open or closed~2. Auditory steady-state response (ASSR)~3. Auditory evoked potential
Study: NCT06746597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking intervention on plantar skin thickness and stiffness
Description: Walking intervention in three different air-insole pressures (80 mmHg, 160 mmHg, 240 mmHg) in two different walking durations (10 and 20 minutes).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking intervention on plantar skin thickness and stiffness
Description: Walking intervention in three different air-insole pressures (80 mmHg, 160 mmHg, 240 mmHg) in two different walking durations (10 and 20 minutes).
Study: NCT06747273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-9004
Description: Intravenous (IV) infusion.
Study: NCT06746376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Description:~Participants assigned to the intervention group will undergo a 8-week supervised hand exercise program designed to improve pain, manual dexterity, and functionality.